To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program.

HR1492 amends Section 1192(e)(1)(A)(ii) of the Social Security Act, changing the market approval requirement for small-molecule drugs to qualify for Medicare price negotiation from 7 years to 11 years. This directly impacts the pharmaceutical industry by delaying price negotiations for these drugs, preserving higher revenue for an extended period. The bill applies retroactively, meaning drugs that would have become eligible for negotiation under the 7-year rule will now have an additional four years before their prices can be negotiated by Medicare. This legislation directly benefits pharmaceutical companies that rely heavily on small-molecule drug development and sales. The additional four years of market exclusivity before price negotiation translates into billions of dollars in retained revenue across the industry. This is not a direct appropriation of funds but rather a regulatory change that prevents a reduction in revenue for drug manufacturers. The money trail is the preservation of existing revenue streams from Medicare Part D and Part B spending on these drugs, which would otherwise be subject to negotiation. Historically, legislative actions that extend market exclusivity or delay price controls for pharmaceuticals have led to positive market reactions for drug manufacturers. For example, the passage of the Medicare Modernization Act in 2003, which established Medicare Part D, led to a sustained bullish trend for pharmaceutical stocks as it expanded the market for prescription drugs. While not directly comparable, any legislation that protects drug pricing power is viewed favorably by the market. The Inflation Reduction Act (IRA) of 2022, which introduced the original 7-year negotiation period, caused significant concern among pharmaceutical companies, leading to a general downturn in the sector's outlook. This bill directly counters a key provision of the IRA. Specific companies that stand to gain include major pharmaceutical manufacturers with significant small-molecule drug portfolios. These include $PFE, $MRK, $BMY, $LLY, $JNJ, $AMGN, $GILD, $VRTX, $REGN, and $BIIB. These companies will see their revenue streams from small-molecule drugs protected for an additional four years. There are no direct losers from this bill among publicly traded companies; the impact is a reduction in potential savings for Medicare and an increase in costs for consumers and taxpayers, but not a direct loss for any specific company. HR1492 has been referred to the Committee on Energy and Commerce and the Committee on Ways and Means. The bill has 66 cosponsors, indicating significant support within the House. Rep. Murphy, a Republican, is the sponsor. The next step involves committee consideration and potential markup. Given the bipartisan cosponsorship and the industry's strong lobbying efforts against the IRA's drug pricing provisions, this bill has a realistic path forward, though passage is not guaranteed. If it passes the House, it would then move to the Senate.